DOCSLIB.ORG

Structural and Functional Studies on Acyl-Coa Carboxylases of Mycobacterium Tuberculosis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Structural and Functional Studies on Acyl-Coa Carboxylases of Mycobacterium Tuberculosis Structural and Functional Studies on Acyl-CoA Carboxylases of Mycobacterium tuberculosis Dissertation submitted to the Combined Faculties for the Natural Sciences and for Mathematics of the Ruperto-Carola University of Heidelberg, Germany for the degree of Doctor of Natural Sciences Madhankumar Anandhakrishnan 2013 Dissertation submitted to the Combined Faculties for the Natural Sciences and for Mathematics of the Ruperto-Carola University of Heidelberg, Germany for the degree of Doctor of Natural Sciences Presented by B.Tech., Madhankumar Anandhakrishnan born in Madurai, India Oral examination: Structural and Functional Studies on Acyl-CoA Carboxylases of Mycobacterium tuberculosis Referees: Dr. Rob Meijers Prof. Dr. Robert B. Russell Contents Table of Contents Summary…………………………………………………………………………….IV Zusammenfassung………………………………………………………………….VI Publications……………………………………………………………………….VIII Abbreviations…………………………………………………………………….....IX 1! Introduction ........................................................................................................... 1! 1.1! Mycobacterium tuberculosis ....................................................................................... 1! 1.1.1! Transmission and pathogenesis............................................................................. 2! 1.1.2! The fight against TB ............................................................................................. 4! 1.1.2.1! Host defence mechanisms ............................................................................. 4! 1.1.2.2! Anti-tuberculosis chemotherapy.................................................................... 6! 1.1.3! The cell wall of Mycobacterium tuberculosis..................................................... 10! 1.1.3.1! Biochemical nature of the cell wall ............................................................. 10! 1.1.3.2! Fatty acid biosynthesis................................................................................. 12! 1.2! Acyl-CoA carboxylase.............................................................................................. 14! 1.2.1! Biotin-dependent carboxylases ........................................................................... 14! 1.2.1.1! Functional components................................................................................ 14! 1.2.1.2! Classification of biotin-dependent carboxylases ......................................... 15! 1.2.2! Actinobacterial acyl-CoA carboxylases.............................................................. 17! 1.2.2.1! Physiological roles of actinobacterial YCCs............................................... 17! 1.2.2.2! Phylogeny of the !-subunits ........................................................................ 18! 1.2.2.3! Quaternary structure of acyl-CoA carboxylases.......................................... 21! 1.2.2.4! Acyl-CoA carboxylases of Streptomyces coelicolor................................... 21! 1.2.2.5! Acyl-CoA carboxylases of Mycobacterium tuberculosis............................ 23! 1.3! Aims of this study ..................................................................................................... 26! 2! Materials and Methods ....................................................................................... 27! 2.1! Materials ................................................................................................................... 27! 2.1.1! Chemicals............................................................................................................ 27! 2.1.2! Fine biochemicals ............................................................................................... 27! 2.1.3! Genomic DNA and bacterial strains ................................................................... 27! 2.1.4! Laboratory consumables ..................................................................................... 28! 2.1.5! Molecular cloning kits ........................................................................................ 29! 2.1.6! Chromatography materials.................................................................................. 29! 2.2! Methods..................................................................................................................... 29! 2.2.1! Preparation of competent cells............................................................................ 29! I Contents 2.2.1.1! Preparation of chemically competent E. coli cells ...................................... 29! 2.2.1.2! Preparation of electrocompetent M. smegmatis cells .................................. 30! 2.2.2! Molecular cloning ............................................................................................... 30! 2.2.2.1! Ligase-dependent cloning............................................................................ 30! 2.2.2.2! Ligase-independent cloning......................................................................... 33! 2.2.3! Heterologous overexpression of proteins............................................................ 35! 2.2.3.1! Large-scale expression of proteins in E. coli............................................... 35! 2.2.3.2! Large-scale expression of proteins in M. smegmatis................................... 35! 2.2.4! Purification of proteins ....................................................................................... 36! 2.2.4.1! IMAC purification of polyhistidine-tagged proteins................................... 37! 2.2.4.2! Size-exclusion chromatography .................................................................. 37! 2.2.4.3! Evaluation of protein biochemical purity .................................................... 38! 2.2.4.4! Protein quantification and concentration..................................................... 39! 2.2.4.5! Verification of protein identity.................................................................... 39! 2.2.5! Reconstitution of protein complexes .................................................................. 40! 2.2.5.1! In vitro reconstitution by purification and co-elution.................................. 40! 2.2.5.2! In vivo reconstitution by co-expression....................................................... 41! 2.2.6! Kinetic characterisation ...................................................................................... 42! 2.2.6.1! Michaelis-Menten kinetics .......................................................................... 42! 2.2.6.2! Assay for carboxylase activity..................................................................... 42! 2.2.7! Biophysical characterisation ............................................................................... 43! 2.2.7.1! Static light scattering ................................................................................... 43! 2.2.7.2! Thermofluor................................................................................................. 44! 2.2.7.3! Circular dichroism spectroscopy ................................................................. 44! 2.2.8! Protein crystallisation.......................................................................................... 45! 2.2.8.1! Principles ..................................................................................................... 45! 2.2.8.2! Screening and optimization ......................................................................... 48! 2.2.8.3! Reductive methylation................................................................................. 48! 2.2.9! X-ray crystallography ......................................................................................... 49! 2.2.9.1! Theory.......................................................................................................... 49! 2.2.9.2! Data collection............................................................................................. 53! 2.2.9.3! Structure solution and refinement................................................................ 53! 2.2.10! Small angle X-ray scattering............................................................................. 54! 3! Results and Discussion ........................................................................................ 56! 3.1! Characterisation of components of the propionyl-CoA carboxylase (PCC) of Mycobacterium tuberculosis............................................................................................... 56! II Contents 3.1.1! Results................................................................................................................. 57! 3.1.1.1! AccA3 and AccD5: formation of a binary complex.................................... 57! 3.1.1.2! AccA3-AccD5 is an active carboxylase ...................................................... 58! 3.1.1.3! Crystallisation.............................................................................................. 59! 3.1.1.4! X-ray data collection, structure solution and refinement ............................ 59! 3.1.1.5! Crystal structure of AccD5.......................................................................... 61! 3.1.1.6! Electron microscopy of AccA3-AccD5....................................................... 66! 3.1.1.7! Overexpression in E. coli............................................................................. 67! 3.1.1.8! Co-expression .............................................................................................. 69! 3.1.1.9! Attempts to improve AccA3 behaviour......................................................
Load more

Recommended publications
  • Treatment Outcomes of Adjunctive Surgery in Multidrug-Resistant And
    MOJ Surgery Opinion Open Access Treatment outcomes of adjunctive surgery in multidrug-resistant and extensively drug-resistant tuberculosis Opinion Volume 5 Issue 2 - 2017 In 2013, the World Health Organization (WHO) reported that 3.5% and 20.5% of new and previously treated tuberculosis (TB) Attapon Cheepsattayakorn,1,2 Ruangrong cases were multidrug-resistant tuberculosis (MDR-TB, resistant 3 to both isoniazid and rifampicin), respectively, and 9.0% of them Cheepsattayakorn 1 developed extensively drug-resistant tuberculosis (XDR-TB, resistant 10th Zonal Tuberculosis and Chest Disease Center, Chiang Mai, Thailand to isoniazid, rifampicin, a fluoroquinolone, and 1 or greater injectable 2Department of Disease Control, Ministry of Public Health, agent). The WHO has estimated a global prevalence of 660,000 cases Thailand of MDR-TB and 150,000 MDR-TB related deaths annually. A previous 3Department of Pathology, Faculty of Medicine, Chiang Mai multi-country study revealed that among 1,278 MDR-TB cases, University, Thailand around 7% had XDR-TB. Only 136,000 MDR-TB cases (45.3%) Correspondence: Attapon Cheepsattayakorn, 10th Zonal among estimated 300,000 MDR-TB cases have been diagnosed and Tuberculosis and Chest Disease Center, 143 Sridornchai Road 97,000 cases (32.3%) are treated using appropriate regimens based on Changklan Muang Chiang Mai 50100 Thailand , Tel 66-531-407- drug susceptibility testing (DST). In 2013, the treatment success rate 67, 66 5-327-636-4, Fax 665-314-077-3, 665-327-359-0, of MDR-TB is only 48.0%; around 47,000 cases improved clinically Email [email protected]; [email protected] and biologically.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Wo 2008/127291 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date PCT (10) International Publication Number 23 October 2008 (23.10.2008) WO 2008/127291 A2 (51) International Patent Classification: Jeffrey, J. [US/US]; 106 Glenview Drive, Los Alamos, GOlN 33/53 (2006.01) GOlN 33/68 (2006.01) NM 87544 (US). HARRIS, Michael, N. [US/US]; 295 GOlN 21/76 (2006.01) GOlN 23/223 (2006.01) Kilby Avenue, Los Alamos, NM 87544 (US). BURRELL, Anthony, K. [NZ/US]; 2431 Canyon Glen, Los Alamos, (21) International Application Number: NM 87544 (US). PCT/US2007/021888 (74) Agents: COTTRELL, Bruce, H. et al.; Los Alamos (22) International Filing Date: 10 October 2007 (10.10.2007) National Laboratory, LGTP, MS A187, Los Alamos, NM 87545 (US). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of national protection available): AE, AG, AL, AM, AT,AU, AZ, BA, BB, BG, BH, BR, BW, BY,BZ, CA, CH, (30) Priority Data: CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, 60/850,594 10 October 2006 (10.10.2006) US ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, (71) Applicants (for all designated States except US): LOS LR, LS, LT, LU, LY,MA, MD, ME, MG, MK, MN, MW, ALAMOS NATIONAL SECURITY,LLC [US/US]; Los MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, Alamos National Laboratory, Lc/ip, Ms A187, Los Alamos, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, NM 87545 (US).
    [Show full text]
  • ANTIBIOTIC INHIBITION of CATALYTIC RNA FUNCTION by Jeff
    ANTIBIOTIC INHIBITION OF CATALYTIC RNA FUNCTION by Jeff Rogers B.Sc. (Honours), University of Regina, 1991 A THESIS SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY in THE FACULTY OF GRADUATE STUDIES (DEPARTMENT OF MICROBIOLOGY AND IMMUNOLOGY) We accept this thesis as conforming to the required standard THE UNIVERSITY OF BRITISH COLUMBIA August 1996 ©Jeff Rogers, 1996 In presenting this thesis in partial fulfilment of the requirements for an advanced degree at the University of British Columbia, I agree that the Library shall make it freely available for reference and study. I further agree that permission for extensive copying of this thesis for scholarly purposes may be granted by the head of my department or by his or her representatives. It is understood that copying or publication of this thesis for financial gain shall not be allowed without my written permission. Department The University of British Columbia Vancouver, Canada DE-6 (2/88) ii ABSTRACT A number of compounds inhibit group I intron splicing. Competitive inhibitors include deoxyguanosine, dideoxyguanosine, arginine and streptomycin; the non-competitive inhibitors include members of the aminoglycoside family of antibiotics. Further screening of a collection of antibiotics for their ability to inhibit group I intron splicing identified several novel compounds. In particular, the pseudodisaccharide antibiotic lysinomicin, the peptide antibiotics netropsin and distamycin, and the tetracycline analog chelocardin, were found to inhibit group I intron splicing at concentrations of 250 pM or lower. Inhibition of group I intron splicing by pseudodisaccharide antibiotics was studied in detail. Lysinomicin and three closely related compounds were found to inhibit the self splicing reaction of the Tetrahymena, Bacillus phage SP01 and T4 phage td and sun 7 group I introns at concentrations less than 50 u.M.
    [Show full text]
  • Molecular Mechanism of Viomycin Inhibition of Peptide Elongation in Bacteria
    Molecular mechanism of viomycin inhibition of peptide elongation in bacteria Mikael Holma, Anneli Borga, Måns Ehrenberga, and Suparna Sanyala,1 aDepartment of Cell and Molecular biology, Uppsala University, 75124 Uppsala, Sweden Edited by Joseph D. Puglisi, Stanford University School of Medicine, Stanford, CA, and approved December 16, 2015 (received for review September 2, 2015) Viomycin is a tuberactinomycin antibiotic essential for treating multi- activity of viomycin in genetic code translation (6) and its stabilization drug-resistant tuberculosis. It inhibits bacterial protein synthesis by of peptidyl tRNA in the A site (24). blocking elongation factor G (EF-G) catalyzed translocation of messen- In this study we used rapid kinetics methods in a state-of-the-art ger RNA on the ribosome. Here we have clarified the molecular aspects in vitro translation system with in vivo-like rates (25, 26) to charac- of viomycin inhibition of the elongating ribosome using pre-steady- terize the mechanism of viomycin inhibition of the peptide elongation state kinetics. We found that the probability of ribosome inhibition by cycle. We constructed a quantitative model for viomycin action with viomycin depends on competition between viomycin and EF-G for precise estimates of the model parameters. This model quantifies the binding to the pretranslocation ribosome, and that stable viomycin functional aspects of viomycin inhibition of translocation. It paves the binding requires an A-site bound tRNA. Once bound, viomycin stalls the way for deeper understanding of the basis of the antimicrobial activity ribosome in a pretranslocation state for a minimum of ∼45 s. This of viomycin and the evolution of viomycin resistance, thereby stalling time increases linearly with viomycin concentration.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Doctoral Thesis
    CHARLES UNIVERSITY IN PRAGUE FACULTY OF PHARMACY IN HRADEC KRÁLOVÉ Doctoral Thesis 2011 Martin Krátký Charles University in Prague Faculty of Pharmacy in Hradec Králové Department of Inorganic and Organic Chemistry Design and Synthesis of New Compounds Active Especially against Multidrug- Resistant Mycobacterial Strains Ph.D. thesis Author: Martin Krátký Study Program: Organic Chemistry Specialization: Bioorganic Chemistry Supervisor: Prof. Dr. Jarmila Vinšová, Ph.D. Hradec Králové December 2011 Universita Karlova v Praze Farmaceutická fakulta v Hradci Králové Katedra anorganické a organické chemie Design a syntéza nových sloučenin působících zejména vůči multilékově resistentním kmenům mykobakterií Disertační práce Autor: Martin Krátký Studijní program: Organická chemie Studijní obor: Bioorganická chemie Školitel: Prof. RNDr. Jarmila Vinšová, CSc. Hradec Králové Prosinec 2011 Prohlašuji, že tato práce je mým původním autorským dílem, které jsem vypracoval samostatně pod vedením prof. RNDr. Jarmily Vinšové, CSc. Veškerá literatura a další zdroje, z nichž jsem při zpracování čerpal, jsou uvedeny v seznamu použité literatury a v práci řádně citovány. I declare that this work is my original authorial work which I developed independently under the supervision of Professor Dr. Jarmila Vinšová, Ph.D. All literature and other sources which I used during processing of this thesis are listed in the list of references and cited properly in the thesis. Hradec Králové, .................................. Abstract Charles University in Prague, Faculty of Pharmacy in Hradec Králové Department of Inorganic and Organic Chemistry Candidate Martin Krátký Supervisor Prof. Dr. Jarmila Vinšová, Ph.D. Title of Doctoral Thesis Design and Synthesis of New Compounds Active Especially against Multidrug-Resistant Mycobacterial Strains This work is focused mainly on the field of searching of new potential antimicrobial agents, particularly against multidrug-resistant Mycobacterium tuberculosis strains, based on the modification of the salicylanilide (2-hydroxy-(N-phenyl)benzamide) group.
    [Show full text]
  • Insights Into Functional Modulation of Catalytic RNA Activity
    IUBMB Life, 60(10): 669–683, October 2008 Critical Review Insights into Functional Modulation of Catalytic RNA Activity Anastassios Vourekas, Vassiliki Stamatopoulou, Chrisavgi Toumpeki, Marianthi Tsitlaidou and Denis Drainas Department of Biological Chemistry, School of Medicine, University of Patras, Rio-Patras, Greece ‘living’ system comprised self-replicases composed of RNA (1). Summary RNA can be both informational and catalytic and therefore can RNA molecules play critical roles in cell biology, and novel provide a logical solution to the ‘chicken and egg’ type of prob- findings continuously broaden their functional repertoires. lem concerning the first living systems at a molecular level. It Apart from their well-documented participation in protein syn- is worth mentioning that the idea that the RNA was the first thesis, it is now apparent that several noncoding RNAs (i.e., micro-RNAs and riboswitches) also participate in the regulation biomolecule was presciently formulated in two famous papers of gene expression. The discovery of catalytic RNAs had pro- by Crick and Orgel in the late 1960s (2, 3). found implications on our views concerning the evolution of life RNA catalysts and other ‘functional’ RNAs (e.g., ribos- on our planet at a molecular level. A characteristic attribute of witches) can naturally or artificially evolve into flexible ‘biosen- RNA, probably traced back to its ancestral origin, is the ability sors’ that can modulate their activity by interacting with a wide to interact with and be modulated by several ions and mole- cules of different sizes. The inhibition of ribosome activity by variety of molecules (4). It is considered that such molecules antibiotics has been extensively used as a therapeutical (e.g., peptides and antibiotics) could have been present in prebi- approach, while activation and substrate-specificity alteration otic conditions (5) assisting primordial reactions.
    [Show full text]
  • Drug Resistance in Mycobacterium Tuberculosis
    Curr. Issues Mol. Biol. 8: 97–112. Online journal at www.cimb.org Drug Resistance in Mycobacterium tuberculosis Rabia Johnson†, Elizabeth M. Streicher†, Gail developed countries (Espinal, 2003). By the end of the E. Louw, Robin M. Warren, Paul D. van Helden, 1960s rifampicin (RIF) was introduced and with the use of and Thomas C. Victor* combination therapy, there was a decline in drug resistant and drug susceptible TB in developed countries. This led DST/NRF Centre of Excellence in Biomedical to a decline in funding and interest in TB control programs. Tuberculosis Research/MRC Centre for Molecular and As a result, no concrete monitoring of drug resistance was Cellular Biology, Division of Molecular Biology and Human carried out for the following 20 years (Espinal, 2003). The Genetics, Department of Biomedical Science, Faculty arrival of HIV/AIDS in the 1980s resulted in an increase of Health Science, Tygerberg, Stellenbosch University, in transmission of TB associated with outbreaks of multi- South Africa drug-resistant TB (MDR-TB) (Edlin et al., 1992; Fischl et al., 1992) i.e. resistant to INH and RIF. In the early 1990s Abstract drug resistance surveillance was resumed in developed Anti-tuberculosis drugs are a two-edged sword. While countries, but the true incidence remained unclear in the they destroy pathogenic M. tuberculosis they also select developing world (Cohn et al., 1997). for drug resistant bacteria against which those drugs are then ineffective. Global surveillance has shown that The WHO/IUATLD global project on drug-resistance drug resistant Tuberculosis is widespread and is now a surveillance threat to tuberculosis control programs in many countries.
    [Show full text]
  • Guidelines for Drug Susceptibility Testing for Second-Line Anti-Tuberculosis Drugs for Dots-Plus
    WHO/CDS/TB/2001.288 Original: English Distr.: General GUIDELINES FOR DRUG SUSCEPTIBILITY TESTING FOR SECOND-LINE ANTI-TUBERCULOSIS DRUGS FOR DOTS-PLUS Communicable Diseases World Health Organization ©World Health Organization, 2001 This document is not a formal publication of the World Health Organization (WHO), and all rights are reserved by the Organization. The document may, however, be freely reviewed, abstracted, reproduced or translated, in part or in whole, but not for sale nor for use in conjunction with commercial purposes. The views expressed herein by named authors are solely the responsibility of those authors. i Acknowledgments Adalbert Laszlo, Marcos A. Espinal, Max Salfinger, Nuria Martin-Casabona, Sabine Rüsch- Gerdes, Sang Jae Kim, Sven Hoffner, and Véronique Vincent, prepared this document. Françoise Portaels, Leen Rigouts and Francis Drobniewski provided useful comments. ii TABLE OF CONTENTS Page Introduction …………………………………………………………………………………. 1 Objectives for guidelines …………………………………………………………………… 2 Objectives for the laboratory ……………………………………………………………….. 2 Technical Issues …………………………………………………………………………….. 2 1. Drugs to be tested …………………………………………………………………….. 2 2. Standard method: Löwenstein Jensen ……………………………………………….. 2 3. Concentrations ……………………………………………………………………….. 3 4. Media preparation, dilutions, inoculation, incubation, and reading …………………. 4 5. Internal quality control procedures for drug susceptibility testing of M. tuberculosis by the proportion method on L-J ………………………………… 5 6. Storage of mybobacteria in 10% skim
    [Show full text]
  • Antitubercular Drugs Pdf
    Antitubercular drugs pdf Continue Tb treatment is aimed at shortening the clinical course of tuberculosis, preventing complications, preventing the development of delay and/or subsequent recurrences, and reducing the likelihood of transmission of tuberculosis. In patients with laten tuberculosis, the purpose of therapy is to prevent the progression of the disease. View full drug information This is the primary drug selected for use in preventive therapy and for use in active tuberculosis combination therapy. It is also used in combination with Rifapentin for adults and children aged 2 years or older with laten TB as a once-weekly DOT therapy for 12 weeks. Its mechanism of action is not fully understood, but isosiosied can inhibit the synthesis of myclic acid, resulting in disruption of the bacterial cell wall. In patients receiving active TB, 25-50 mg of pyridoxin should be taken orally once a day to prevent peripheral neuropathy. See the full drug information Rifampin is used in co-ed with at least 1 other anti-tuberculosis drug active in TB. Inhibits DNA-dependent RNA polymerase activity in bacterial cells, but not mammalian cells. Cross resistance may occur. In most susceptible cases, the patient undergoes 6 months of treatment. Treatment lasts for 9 months if the patient's sputum herniation results are positive after 2 months of treatment. View full drug information This is an analogue of nicotinamide pirazine, which is bacteriostatic or bactericidal against M tuberculosis, depending on the concentration of the drug reached at the site of infection. The mechanism of action of pyrazinamide is unknown. Inject the drug into the initial 2 months of a 6-month or longer treatment regimen with drug-sensitive TB.
    [Show full text]
  • WO 2013/086415 Al 13 June 2013 (13.06.2013) W P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2013/086415 Al 13 June 2013 (13.06.2013) W P O P C T (51) International Patent Classification: Irosha [LK/US]; 2007 Huron Parkway #2, Ann Arbor, C07D 265/34 (2006.01) Michigan 48104 (US). KIRCHHOFF, Paul D. [US/US]; 9670 Sherwood Drive., Saline, MI 48176 (US). (21) International Application Number: PCT/US2012/068570 (74) Agent: CASIMIR, David A.; Casimir Jones, S.C., 2275 Deming Way, Suite 310, Middleton, WI 53562 (US). (22) International Filing Date: 7 December 2012 (07.12.2012) (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (25) Filing Language: English AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (26) Publication Language: English BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (30) Priority Data: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, 61/569,100 9 December 201 1 (09. 12.201 1) US KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (71) Applicant: THE REGENTS OF THE UNIVERSITY ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, OF MICHIGAN [US/US]; 1600 Huron Parkway, 2nd NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, Floor, Ann Arbor, Michigan 48109-2590 (US). RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, (72) Inventors; and ZM, ZW.
    [Show full text]